This company has shut down. Axcella is no longer operating — its last tracked round was a Post-IPO Equity in 2022.
Explore the Startup GraveyardAxcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Axcella has raised $34.2M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2022.
Axcella's investors include Fidelity, Flagship Pioneering, Nestlé Health Science, Enso Ventures, Rajiv Kaul.
Axcella is headquartered in Cambridge, United States.
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Axcella is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Axcella — Funding & Investors." VCBacked, October 13, 2022, https://www.vcbacked.co/company/axcella. Accessed September 30, 2026.
VCBacked. (2022). Axcella — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/axcella
{{cite web |title=Axcella — Funding & Investors |url=https://www.vcbacked.co/company/axcella |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated